William M Tauxe1, John P Haydek1, Paulina A Rebolledo2, Emma Neish3, Kira L Newman4, Angela Ward5, Tanvi Dhere6, Colleen S Kraft7. 1. Emory University School of Medicine, Atlanta, GA, USA. 2. Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 3. Emory University, Atlanta, GA, USA. 4. Department of Epidemiology, Emory University, Atlanta, GA, USA. 5. Emory Healthcare, Atlanta, GA, USA. 6. Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA, USA. 7. Division of Infectious Diseases, Emory University School of Medicine, Department of Pathology and Laboratory Medicine, Emory University Hospital, F145C, 1364 Clifton Rd, Atlanta, GA 30322, USA.
Abstract
BACKGROUND: The objective of this study was to describe the safety of fecal microbiota transplant (FMT) for Clostridium difficile infection (CDI) among older adults. METHODS: We performed a case review of all FMT recipients aged 65 or older treated at Emory University Hospital, a tertiary care and referral center for Georgia and surrounding states. RESULTS: CDI resolved in 27 (87%) of 31 respondents, including three individuals who received multiple FMTs. Among four whose CDI was not resolved at follow up, three respondents did well initially before CDI recurred, and one individual never eradicated his CDI despite repeating FMT. During the study, five deaths and eight serious adverse events requiring hospitalization were reported within the study group during the follow-up period. Fecal transplant was not a causative factor in these events. The most common adverse event reported in 4 (13%) of 31 respondents was subjective worsening of arthritis. CONCLUSION: FMT is a generally safe and effective treatment option for older adults with CDI.
BACKGROUND: The objective of this study was to describe the safety of fecal microbiota transplant (FMT) for Clostridium difficile infection (CDI) among older adults. METHODS: We performed a case review of all FMT recipients aged 65 or older treated at Emory University Hospital, a tertiary care and referral center for Georgia and surrounding states. RESULTS: CDI resolved in 27 (87%) of 31 respondents, including three individuals who received multiple FMTs. Among four whose CDI was not resolved at follow up, three respondents did well initially before CDI recurred, and one individual never eradicated his CDI despite repeating FMT. During the study, five deaths and eight serious adverse events requiring hospitalization were reported within the study group during the follow-up period. Fecal transplant was not a causative factor in these events. The most common adverse event reported in 4 (13%) of 31 respondents was subjective worsening of arthritis. CONCLUSION: FMT is a generally safe and effective treatment option for older adults with CDI.
Authors: Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun Journal: Am J Gastroenterol Date: 2013-02-26 Impact factor: 10.864
Authors: Manasi Agrawal; Olga C Aroniadis; Lawrence J Brandt; Colleen Kelly; Sarah Freeman; Christina Surawicz; Elizabeth Broussard; Neil Stollman; Andrea Giovanelli; Becky Smith; Eugene Yen; Apurva Trivedi; Levi Hubble; Dina Kao; Thomas Borody; Sarah Finlayson; Arnab Ray; Robert Smith Journal: J Clin Gastroenterol Date: 2016 May-Jun Impact factor: 3.062
Authors: R Caliskan; S Masatlioglu; M Aslan; S Altun; S Saribas; S Ergin; E Uckan; V Koksal; V Oz; K Altas; I Fresko; B Kocazeybek Journal: Rheumatol Int Date: 2004-08-20 Impact factor: 2.631
Authors: Rodrigo Duarte-Chavez; Thomas R Wojda; Thomas B Zanders; Berhanu Geme; Gloria Fioravanti; Stanislaw P Stawicki Journal: J Glob Infect Dis Date: 2018 Apr-Jun
Authors: Gianluca Ianiro; Marcello Maida; Johan Burisch; Claudia Simonelli; Georgina Hold; Marco Ventimiglia; Antonio Gasbarrini; Giovanni Cammarota Journal: United European Gastroenterol J Date: 2018-06-03 Impact factor: 4.623